This multicenter study highlights the critical role of ID pharmacists in supporting ID consult services, with 89% of 1,518 curbside inquiries from ID clinicians resulting in clinical management changes as recommended by the pharmacist. These findings emphasize the necessity of ID pharmacists in optimizing multidisciplinary patient care.

Ashraf S Ibrahim, PhD, discusses how VX-01 prevents fungal invasion of blood vessels and enhances immune response in immunocompromised patients.

Burns intensive care units (BICU) have reduced mortality in burns patients, but infections and sepsis remain the leading causes of death.

This study assessed the pharmacokinetic interactions between dolutegravir (DTG)-based antiretroviral therapy (ART) and immunosuppressants in solid organ transplantation (SOT) recipients with human immunodeficiency virus (HIV) and ART safety.

Viral blips have been associated with larger reservoir size and slower decay. Earlier antiretroviral therapy (ART) initiation may decrease the risk of blips.

The Infectious Diseases Society of America journals Clinical Infectious Diseases and Open Forum Infectious Diseases are seeking qualified associate editors for several open positions on their editorial boards. ID-trained physicians, PhDs, and ID pharmacists (PharmDs) are welcome to apply.

Abstract. Illicit drug use in the United States continues to rise, alongside an increasing number of severe infections associated with drug use. Surveillan

Macrolide-Resistant <em>M. pneumoniae</em> among Children

To the Editor - We thank Drs. Sakuraia, Ishikanea, and Ohmagaria for their interest in the CFAR Network of Integrated Clinical Systems (CNICS) cohort study of mpox among people with HIV (PWH). While we agree that there are limitations to our data as in any study, noted in our discussion, we offer additional context for the CNICS cohort to address the authors’ concerns.

Sean Ong discusses how persistent fever beyond 72 hours emerges as a stronger predictor of mortality in MRSA bacteremia compared to CRP and WBC counts.

Clinical science in the field of infectious diseases moved at a rapid pace in 2024. Among the highlights were multiple trials of new antibiotics and new approaches to prevent infections. Concerning trends, with outbreaks of dengue, measles, mpox, and highly pathogenic avian influenza A in 2024, demonstrate the importance of infectious diseases and the continued need for further advances through clinical science. This review highlights some of the most important trials and clinical trends in infectious diseases over the past year.

Infective endocarditis (IE) among people who inject drugs (PWID) has been associated with better short-term outcome. Long-term outcome of PWID with IE is poorly known.

FDA investigates ongoing outbreaks involving contaminated pastries with 18 reported cases of illness across 7 states, and 1 hospitalization.

In this issue of CID, there are two papers on the topic of high-dose rifamycins for tuberculosis[1- 2]. It is fair to say there is a growing consensus (but not unanimity) on the idea that rifampin 600 mg is a “suboptimal” dose. The seeds for this idea go back to the introduction of rifampin in 1971, and even further back into its development.